Deputy Chief Scientific Officer, Senior Director of Scientific Operations and Veterinary Science, CiToxLAB Dr. Authier obtained a doctor in veterinary medicine degree from the University of Montreal and specialized in nonclinical studies after completing a PhD in preclinical pharmacology. He then completed a MBA in corporate finances and management. Over the past years, Dr. Authier investigated methodologies in nonclinical regulatory safety pharmacology studies with the objective of improving study designs for optimal sensitivity and decision making in this field. Dr. Authier overviews the work of a team of scientists and veterinarians specialized preclinical research for IND, BLA and NDA filing with a focus on safety pharmacology. He participated in face-to-face US FDA pre-IND meetings and overviewed conduct of preclinical studies for a number of small and large molecules over the last 14 years working at CIToxLAB North America. He was an invited speaker at various scientific conferences including the US Food and Drug Administration (FDA), Canadian Society of Quality Assurance, the Safety Pharmacology Society, American College of Toxicologists (ACT), Japanese Society of Safety Pharmacology and the American Association of Laboratory Animal Science to name a few. For the last seven years, Dr. Authier was an invited professor in immunolgy and pharmacology at University of Montreal, Canada. To date, Dr. Authier has provided scientific overview for more than 800 studies assessing cardiovascular, respiratory, neurological, gastrointestinal, and renal safety pharmacology.
Leanne received her PhD in Pharmacology and Toxicology from Queen’s University (Kingston, ON, Canada). Leanne began her career in pharmaceutical research at Merck Frosst in Montréal where she contributed to the discovery of PIFELTRO™, now marketed for the treatment of HIV. Leanne then joined AstraZeneca R&D Montréal as a DMPK Drug Design Leader.
For the past decade, Leanne has worked as a consultant in nonclinical drug metabolism, pharmacokinetics and toxicology. Leanne has also served as a Nonclinical Pharm/Tox Reviewer to Health Canada.
Leanne is currently President of the Roundtable of Toxicology Consultants. She recently authored the book chapter on Toxicokinetics for the revised 7th Edition of Hayes’ Principles and Methods of Toxicology.
Dr. Bill Brock received his PhD in toxicology from the University of Kentucky (1983), and did a postdoctoral fellowship at UK. From his postdoctoral fellowship, he joined DuPont’s Haskell Laboratory and spent 17 years in various research, testing and management roles. Subsequently, Bill joined Unilever, a worldwide consumer product company, and then the international consulting firm Environ. In 2004, he became an independent toxicology consultant. He is the Director of Toxicology for Otsuka Pharmaceuticals.
Dr. Brock provides pharmacology and toxicology research and testing advice for early- through late-stage pharmaceutical development for worldwide regulatory submissions. Furthermore, he provides scientific and regulatory consulting advice and safety and risk assessments to clients in the chemical, medical device, food and consumer product industries. His primary research interests include human health risk and exposure assessments with an interest in the mechanisms of toxicity associated with human exposures to xenobiotics. Dr. Brock has authored or co-authored more than 50 publications, and has authored or coauthored several book chapters and is a co-editor on two toxicology and regulatory books. He has served as a member and in a leadership capacity for several national and international toxicology organizations. Dr. Brock is currently an expert reviewer for IPEC’s Excipients Panel.
Dr. Brock is a Diplomate of ABT, a Fellow of ATS, and has served as a Board member and President for both ABT and ATS. Dr. Brock has served in various leadership capacities or as a member of various professional organizations and committees for the ACT, SOT and others. Dr. Brock is an Associate Editor for the International Journal of Toxicology, and a reviewer for Food and Chemical Toxicology, Toxicological Sciences, Toxicology and Industrial Health, Current Eye Research and other leading toxicology journals.
Lydia is the Director of Regulatory Affairs at Nichino America, Inc., a wholly owned subsidiary of Nihon Nohyaku Co. Ltd., Japan’s first and oldest agrochemical manufacturing company. In her current role, she leads the regulatory affairs team based in Wilmington, DE and is focused on the development, registration, and stewardship of products for the crop protection sector in the US and Canada. She has a BS in animal science from Cornell University and a PhD in toxicology from University of the Sciences in Philadelphia, Pennsylvania. After completing her postdoctoral training at New York University’s Institute of Environmental Medicine in Tuxedo, New York, Lydia joined DuPont’s Haskell Global Centers for Health and Environmental Sciences. While at DuPont, she worked in various roles as a toxicologist including study director and monitor for mammalian studies, group leader in genetic toxicology, and toxicology liaison to provide strategic guidance for registration and stewardship initiatives. She has also worked as a toxicology consultant for Critical Path Services in Garnet Valley, Pennsylvania for projects in the industrial chemical, medical device, and cosmetic sectors. She is a Diplomate of the American Board of Toxicology.
Dr. Greg Finch is currently an independent research toxicologist following his retirement from Pfizer’s Drug Safety Research and Development group in Groton, CT. He earned his PhD in Chemical Ecology from the University of California, Davis, and then joined the Lovelace Respiratory Research Institute in Albuquerque, NM. Dr. Finch’s research at Lovelace focused on the use of animal models to characterize respiratory tract responses to inhaled materials, the disposition of these materials from the respiratory tract, and application to human health risk assessment. He subsequently joined Pfizer, where his research initially focused on inhaled drug development and in characterizing the safety and fate of inhaled macromolecules in the lung. He was part of a team that gained regulatory approval for the first inhaled insulin drug product. Dr. Finch has been a Drug Safety team leader in numerous projects in oncology, respiratory, and antiviral therapeutic areas, and has participated in advancing several drugs through registration. He conducted due diligence reviews of potential licensing candidates and safety evaluations of novel drug development technologies. Dr. Finch represented Pfizer in several external pharmaceutical industry groups. He is a member of the Society of Toxicology and is a Diplomate of the American Board of Toxicology (1990–2025), with service on the ABT Board of Directors. He currently contributes to the advancement of toxicological science by volunteering for special projects (ABT, ACT) and as a journal reviewer.
Dr. Mary Beth Genter has been an academic toxicologist since completing graduate studies in the Integrated Toxicology Program at Duke University and postdoctoral studies at the Chemical Industry Institute of Toxicology in 1990. Dr. Genter’s background is in neurotoxicology, and she has a special interest in the olfactory system, both as a target for toxicant-induced damage and as a route of drug delivery. Prior to joining the University of Cincinnati Department of Environmental Health, Dr. Genter was employed by the North Carolina State University Department of Toxicology, where, among other responsibilities, she served as the toxicologist for the North Carolina Cooperative Extension Service. She also served as a member of the North Carolina Secretary’s Scientific Advisory Board on Toxic Air Pollutants. Dr. Genter has published over 70 peer-reviewed manuscripts, and served as an advisor for the USEPA during the reevaluation of the IRIS naphthalene document. Dr. Genter is a diplomate of the American Board of Toxicology (ABT; 1992-present) and served on the ABT Board of Directors (2004-2008). She was named a Fellow of the Academy of Toxicological Scientists in 2012. She is currently (2008-present) Editor-in-Chief of International Journal of Toxicology, the official journal of the American College of Toxicology, where she also serves as a Councilor. Dr. Genter is also a member of the Toxicology in Vitro Editorial Board, and a reviewer for approximately 2 dozen papers for other journals per year. Dr. Genter serves on the Council of the Society of Toxicology (2016–2019) and recently completed a term on the National Toxicology Program Board of Scientific Counselors (2013–2017). She is a member of the American College of Toxicology, the Society of Toxicology, the Association for Chemoreception Sciences, and Sigma Xi.
Dr. Hoberman has been employed by Charles River Laboratories, Preclinical Services, Pennsylvania (formerly Argus Research Laboratories, Inc.) since 1981. Currently he is Executive Director, Global Developmental, Reproductive, and Juvenile Toxicology. He is a Diplomat of the American Board of Toxicology and a Fellow of the Academy of Toxicological Sciences, with over 85 publications and book chapters. He is the co-editor of Pediatric Non-Clinical Drug Testing, Principles, Requirements, and Practices published in January 2012.
Dr. Hoberman has been a member of the American College of Toxicology since 1979 and is currently the Treasurer. He has been a member of the Teratology Society since 1978 and is currently the Vice-President. He is past president of the Reproductive and Developmental Toxicity Specialty Section of the Society of Toxicology and past president of the Middle Atlantic Reproductive and Teratology Association, as well as past president of the Arkansas Biotechnology Organization.
Dr. Hoivik received her PhD in toxicology from the University of Connecticut and conducted her postdoctoral research at Texas A&M. She spent eight years at GlaxoSmithKline in a variety of roles in Medicine Safety where she was responsible for the nonclinical product development strategy and execution as well as regulatory interactions and submissions for new therapeutic entities. Dr. Hoivik joined Boehringer-Ingelheim Pharmaceuticals in 2005 and she was the Director of Toxicology Operations. She is currently at Akebia Therapeutics. Dr. Hoivik has authored five invited book chapters, 24 peer reviewed manuscripts, and 25 abstracts. She has served ACT in a variety of roles (e.g., Councilor, Secretary, Continuing Education Committee, Nominating Committee, Program Committee); she is currently Co-Chair of the SOT Education Committee; served on the SOT Communication Committee; and she is currently the President of the Northeast Society of Toxicology. Dr. Hoivik has also served on multiple pharmaceutical consortiums and workgroups. She has been a member of the Editorial Review Board for the International Journal of Toxicology since 2004 and serves as a reviewer for Toxicological Sciences. Dr. Hoivik was certified by the American Board of Toxicology in 1999.
Dr. Lane earned a bachelor’s degree in chemistry from Dartmouth College and a doctorate in pharmacology from Virginia Commonwealth University. His work experience has ranged from directing and overseeing preclinical toxicology studies to management-level positions in global industries directing worldwide safety programs. Most of Dr. Lane’s career was spent at Unilever and PepsiCo where he advised the foods and beverages businesses in the areas of toxicology, risk assessment, exposure evaluation, product safety and regulatory affairs. His responsibilities included providing strategic technical input to senior management and legal, toxicology, and food safety experts globally. Dr. Lane also served as the chief technical liaison to major trade associations and scientific organizations for food chemical safety. He is now an independent consultant providing toxicology advice for food ingredient development and regulatory submissions to food companies in the United States and Europe. Dr. Lane is a member of the American College of Toxicology and the Society of Toxicology, where he was the President of the Food Safety Specialty Section. Until his retirement from PepsiCo he was a member of The Toxicology Forum where he served as Vice President and Interim President. Dr. Lane was a Diplomate of the American Board of Toxicology for 35 years. He has authored or co-authored peer-reviewed publications, presentations and book chapters. Dr. Lane has been on the editorial boards of the International Journal of Toxicology and Food and Chemical Toxicology, and reviewed submissions for Regulatory Toxicology and Pharmacology, and other leading toxicology journals.
Dr. Tom Lewandowski is a toxicologist and chemist working in Gradient’s Seattle, Washington office. He received his PhD in toxicology from the University of Washington School of Public Health. He also holds an MPH in environmental health from the University of Michigan. Dr. Lewandowski has over 30 years of experience in the areas of risk assessment, product safety evaluation, pharmacokinetics, and metals toxicology. Current areas of particular interest include skin sensitization, cannabinoids, and chemical alternatives assessment. He is board certified as a toxicologist in both the US (DABT) and Europe (ERT). He is also a fellow of the Academy of Toxicological Sciences (ATS). He was previously an Associate Professor of environmental health at Brooklyn College/The City University of New York where he taught courses in environmental health, human physiology, and sustainability. He is currently an affiliate faculty member at the University of Washington School of Public Health where he lectures on metals toxicology and risk assessment. He is the author of numerous publications related to risk assessment methods (in particular the use of computational models). He is a member of the OARS WEEL committee, which reviews toxicology data to develop workplace exposure guidelines for new chemical agents. He is also currently an officer of the SOT Dermal Toxicology Specialty Section.
Dr. McMillan graduated from the Department of Biomedical Engineering at Vanderbilt University, and received his PhD in Toxicology from the University of Rochester School of Medicine and Dentistry. He then completed a postdoctoral fellowship at the University of Vermont Medical Center in the Department of Pathology and Laboratory Medicine. Dr. McMillan joined the US Food & Drug Administration in 2016 and is now a Senior Toxicologist in the Division of Pharmacology/Toxicology for Infectious Disease, assigned to the Division of Antivirals. He became a Diplomate of the American Board of Toxicology in 2018.
Dr. Leslie Recio is the Chief Scientific Officer at ScitoVation. Current research studies are focused on integrating gene expression profiling with apical endpoints assessed in rodents, hepatocytes and human cell lines toxicology models. Dr. Recio received his MS and PhD from the University of Kentucky conducting his doctoral research in mammalian cell mutagenesis at the Biology Division of Oak Ridge National Laboratory and in 1986, Dr. Recio was a postdoctoral fellow at CIIT. Dr. Recio has authored or co-authored 80 peer reviewed publications in the areas of mutagenesis, toxicogenomics and regulatory based genotoxicity assessment. In 2010, Dr. Recio was appointed to the SOT Council on Diversity Initiatives. In 2011, he was elected as the 2012 president of the Hispanic Organization of Toxicologist. Dr. Recio was on the 5th International Working Group for Genotoxicity Testing in focused on integration of genotoxicity with standard rodent toxicology testing. In 2012, Dr. Recio was appointed to the OECD Genetic Toxicology Expert Group charged with revising OECD test guidelines for regulatory genetic toxicology testing in mammalian cells. In 2012, Dr. Recio was named Director of Genomics for ILS Genomics. He is part of an ILSI/HESI Genomics Committee collaboration developing methods for gene expression profiling from FFPE tissues using microarrays and next generation sequencing technologies. Dr. Recio currently serves on the Editorial Boards for Toxicological Sciences and Mutation Research—Reviews in Mutation Research.
Dr. Robert Roy has been a toxicologist at 3M for over 22 years. Rob is currently a Lead Toxicology Specialist in the 3M Corporate Toxicology and Environmental Sciences group. At 3M he has been actively involved in the support of the global toxicology (and regulatory toxicology) efforts of many of 3M divisions and business units. Some of these toxicologically-related activities include the placing, monitoring and evaluation of both short-term and longer-term toxicity studies, the health hazard assessment of raw materials, intermediates, and finished industrial and consumer products, and the preparation of human health risk/safety assessments for industrial and consumer products (including for Prop65). He also derives all DNELs and DMELs used in 3M REACH registrations, has been the Chair of the 3M OEL committee for over 20 years, and serves on many internal 3M committees and work groups.
Rob has been a Diplomate of the ABT since 1994 and served on the ABT Board of Directors from 2013 – 2017. He is actively involved in teaching and advising students at the graduate level at University of Minnesota where he is an Adjunct Associate Professor in the School of Public Health (Toxicology Graduate Program). He also serves on the editorial boards of toxicology journals, is actively involved in development and teaching of CE courses in toxicology for the Society of Chemical Hazard Communication (SCHC) and is a faculty member in the Graduate Program in Product Stewardship at Indiana University. Rob is a Fellow of the Academy of Toxicological Sciences (ATS), has served on the SOT CE Committee, is a 25-year member of the national OEL-developing Workplace Environmental Exposure Levels (WEEL) Committee, is a member of the NIOSH Board of Scientific Counselors (BSC) and serves/has served on several other ACC, University of Minnesota, AIHA, ECETOC-sponsored committees and work groups
Robert Skoglund PhD, DABT, CIH, CPPS is the Head of Product Safety and Regulatory Affairs for Covestro LLC, a world-leading manufacturer of high-tech, durable polymer materials. With over 30 years of experience in the EHS field, he has developed a strong background in regulatory and applied toxicology, environmental chemistry, industrial hygiene, and chemical management regulations. Dr. Skoglund serves as an adjunct professor in the Schools of Public Health at the University of Minnesota and Indiana University and has or is serving as an advisor to the Environmental Protection Agency, the National Institute of Environmental Health Sciences, and the National Academy of Sciences. In addition, he has published a number of peer reviewed abstracts, articles, and book chapters and is active in a number of relevant professional and trade organizations. Dr. Skoglund earned his MS and PhD from the University of Minnesota and is board certified in toxicology, industrial hygiene, and product stewardship.